Defence Therapeutics (TSE:DTC) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Defence Therapeutics has announced receiving a No Objection Letter from Health Canada for a Phase I clinical trial of its anti-cancer molecule, ACCUM-002, aimed at treating melanoma. The trial will assess the safety, tolerability, and preliminary efficacy of the molecule, both as a standalone treatment and in combination with Opdualag, a known immunotherapy. With the global cancer immunotherapy market expected to grow significantly, Defence is positioning itself as a potential leader in innovative cancer treatments.
For further insights into TSE:DTC stock, check out TipRanks’ Stock Analysis page.